Eli Gilboa
YOU?
Author Swipe
View article: A Novel Artificial Endothelial Replacement Membrane for the Treatment of Chronic Corneal Edema
A Novel Artificial Endothelial Replacement Membrane for the Treatment of Chronic Corneal Edema Open
Purpose: The purpose of this study was to report the safety and efficacy results of an artificial lamellar implant for the treatment of chronic corneal edema. Methods: The EndoArt (EyeYon Medical, Ness Ziona, Israel), an artificial endothe…
View article: FIGURE 5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Addition of αPD-1 blockade to Uro A treatment further decreases PDAC tumor burden and improves overall survival in PKT mice. A, Schematic representation of PKT mice treated with vehicle, Uro A, or Uro A in combination with aPD-1. B, Kaplan…
View article: FIGURE 4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
PD-1/PD-L1 expression in the PDAC TME with Uro A treatment. A, Immunofluorescence-based histologic analysis depicting PD-L1–positive cells within pancreatic tumor sections harvested from vehicle or Uro A-treated PKT mice. Mean of positive …
View article: FIGURE 2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Treatment with PI3Ki (Omipalisib) recapitulates antitumor and immunomodulatory benefits of Uro A in PDAC. A, Schematic of PI3Ki (Omipalisib) treatment in PKT mice. B, Pancreas weight analysis of PI3Ki- or vehicle-treated PKT mice, n = 3–4 …
View article: FIGURE 2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Treatment with PI3Ki (Omipalisib) recapitulates antitumor and immunomodulatory benefits of Uro A in PDAC. A, Schematic of PI3Ki (Omipalisib) treatment in PKT mice. B, Pancreas weight analysis of PI3Ki- or vehicle-treated PKT mice, n = 3–4 …
View article: Figure S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Raw uncropped images of Western blot membranes for Figs. 2e, 2f, S3a and S3b.
View article: Figure S3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Gating strategies used for flow cytometry analysis.
View article: Figure S1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Raw uncropped images of Western blot membranes for Figs.1e and 3d.
View article: Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Tumor weight, mouse weight and cytokine profiling of Uro A treatment in PKT mice.
View article: FIGURE 3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Uro A treatment reduces immunosuppressive TAM populations, facilitates intratumoral T-cell infiltration and controls PDAC growth in a T cell–dependent manner. Single-cell suspensions of pancreatic tumors obtained from PKT mice treated with…
View article: FIGURE 1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Uro A treatment downregulates PI3K/AKT/mTOR pathway, reduces primary tumor burden, alters the stromal composition and immunomodulatory profile of the TME in a spontaneous murine model of PDAC. A, mRNA levels of AKT1 in normal pancreatic ti…
View article: Figure S7 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S7 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Recorded body weights of PKT mice treated with Uro A, aPD-1 and Uro A+aPD-1.
View article: Figure S6 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S6 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
PD-L1 expression in Uro A or PI3Ki treated KPC cells.
View article: Figure S5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Cytokine profiling of PKT tumors and KPC cells treated with PI3Ki or Uro A.
View article: Figure S6 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S6 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
PD-L1 expression in Uro A or PI3Ki treated KPC cells.
View article: FIGURE 1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Uro A treatment downregulates PI3K/AKT/mTOR pathway, reduces primary tumor burden, alters the stromal composition and immunomodulatory profile of the TME in a spontaneous murine model of PDAC. A, mRNA levels of AKT1 in normal pancreatic ti…
View article: Figure S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Raw uncropped images of Western blot membranes for Figs. 2e, 2f, S3a and S3b.
View article: Figure S1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Raw uncropped images of Western blot membranes for Figs.1e and 3d.
View article: Figure S7 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S7 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Recorded body weights of PKT mice treated with Uro A, aPD-1 and Uro A+aPD-1.
View article: FIGURE 5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Addition of αPD-1 blockade to Uro A treatment further decreases PDAC tumor burden and improves overall survival in PKT mice. A, Schematic representation of PKT mice treated with vehicle, Uro A, or Uro A in combination with aPD-1. B, Kaplan…
View article: Data from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Data from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is a significant contributor to cancer-related morbidity and mortality, and it is known for its resistance to conventional treatment regimens, including chemotherapy and immune checkpoint blockade (I…
View article: FIGURE 3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Uro A treatment reduces immunosuppressive TAM populations, facilitates intratumoral T-cell infiltration and controls PDAC growth in a T cell–dependent manner. Single-cell suspensions of pancreatic tumors obtained from PKT mice treated with…
View article: Figure S3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S3 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Gating strategies used for flow cytometry analysis.
View article: FIGURE 4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
FIGURE 4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
PD-1/PD-L1 expression in the PDAC TME with Uro A treatment. A, Immunofluorescence-based histologic analysis depicting PD-L1–positive cells within pancreatic tumor sections harvested from vehicle or Uro A-treated PKT mice. Mean of positive …
View article: Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Tumor weight, mouse weight and cytokine profiling of Uro A treatment in PKT mice.
View article: Supplementary Tables S1-S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Supplementary Tables S1-S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Primary antibodies for flow cytometry, immunohistochemistry and Western blot analysis.
View article: Figure S5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Figure S5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Cytokine profiling of PKT tumors and KPC cells treated with PI3Ki or Uro A.
View article: Supplementary Tables S1-S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer
Supplementary Tables S1-S2 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Open
Primary antibodies for flow cytometry, immunohistochemistry and Western blot analysis.